{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:04:06Z","timestamp":1788343446314,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T00:00:00Z","timestamp":1568332800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T00:00:00Z","timestamp":1568332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s11095-019-2686-4","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T16:03:47Z","timestamp":1568390627000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Glycine-Poly-L-Lactic Acid Copolymeric Nanoparticles for the Efficient Delivery of Bortezomib"],"prefix":"10.1007","volume":"36","author":[{"given":"Sudhakar","family":"Rajoria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita","family":"Rani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dasharath","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanyog","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8947-2749","authenticated-orcid":false,"given":"Umesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,13]]},"reference":[{"key":"2686_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer statistics GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"2686_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.eurpolymj.2017.05.036","volume":"93","author":"S Medela","year":"2017","unstructured":"Medela S, Syrovab Z, Kovacik L, Hrdy J, Hornacek M, Jager E, et al. Curcumin-bortezomib loaded polymeric nanoparticles for synergistic cancer therapy. Eur Polym J. 2017;93:116\u201331.","journal-title":"Eur Polym J"},{"key":"2686_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2174\/156800911794519752","volume":"11","author":"D Chen","year":"2011","unstructured":"Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011;11:239\u201353.","journal-title":"Curr Cancer Drug Targets"},{"key":"2686_CR4","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, De Vos S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867\u201374.","journal-title":"J Clin Oncol"},{"key":"2686_CR5","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1200\/JCO.2004.02.106","volume":"22","author":"CN Papandreou","year":"2004","unstructured":"Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004;22:2108\u201321.","journal-title":"J Clin Oncol"},{"key":"2686_CR6","first-page":"2615","volume":"59","author":"J Adams","year":"1999","unstructured":"Adams J, Palombella VJ, Sausville EA. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615\u201322.","journal-title":"Cancer Res"},{"key":"2686_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nrc1361","volume":"4","author":"J Adams","year":"2004","unstructured":"Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4:349\u201360.","journal-title":"Nat Rev Cancer"},{"key":"2686_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1368-7646(02)00121-8","volume":"5","author":"TR Pray","year":"2002","unstructured":"Pray TR, Parlati F, Huang J, Wong BR, Payan DG, Bennett MK, et al. Cell cycle regulatory E3 ubiquitin ligases as anticancer targets. Drug Resist. 2002;5:249\u201358.","journal-title":"Drug Resist"},{"key":"2686_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.canlet.2012.05.015","volume":"2","author":"S Nowsheen","year":"2014","unstructured":"Nowsheen S, Aziz K, Tran PT. Epigenetic inactivation of DNA repair in breast cancer. Cancer Lett. 2014;2:213\u201322.","journal-title":"Cancer Lett"},{"key":"2686_CR10","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3892\/or.2016.4873","volume":"36","author":"M Maynadier","year":"2016","unstructured":"Maynadier M, Basile I, Gallu AD, Gary-Bobo ML, Garcia M. Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer. Oncol Rep. 2016;36:1127\u201334.","journal-title":"Oncol Rep"},{"key":"2686_CR11","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/ijc.29404","volume":"13","author":"S Thaler","year":"2015","unstructured":"Thaler S, Thiede G, Hengstler JG, Schad A, Schmidt M, Sleeman JP. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer. Int J Cancer. 2015;13:686\u201397.","journal-title":"Int J Cancer"},{"key":"2686_CR12","doi-asserted-by":"publisher","first-page":"72281","DOI":"10.18632\/oncotarget.20261","volume":"8","author":"S Thaler","year":"2017","unstructured":"Thaler S, Schmidt M, Ro\u00dfwag S, Thiede G, Schad A, Jonathan P, et al. Proteasome inhibitors prevent bi-directional HER2\/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+\/ER+ breast cancer cells. Oncotarget. 2017;8:72281\u2013301.","journal-title":"Oncotarget."},{"key":"2686_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41389-018-0086-y","volume":"7","author":"X Xia","year":"2018","unstructured":"Xia X, Liao Y, Guo Z, Li Y, Jiang L, Zhang F, et al. Targeting proteasome-associated deubiquitinases as a novel strategy for the treatment of estrogen receptor-positive breast cancer. Oncogenesis. 2018;7:75.","journal-title":"Oncogenesis."},{"key":"2686_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1081\/DMR-100101909","volume":"31","author":"ML Rose","year":"1999","unstructured":"Rose ML, Rusyn I, Bojes HK, Germolec DR, Luster M, Thurman RG, et al. Role of kupffer cells in peroxisome proliferator-induced hepatocyte proliferation. Drug Metab Rev. 1999;31:87\u2013116.","journal-title":"Drug Metab Rev"},{"key":"2686_CR15","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/carcin\/20.5.793","volume":"20","author":"ML Rose","year":"1999","unstructured":"Rose ML, Madren J, Bunzendahl H, Thurman RG. Dietary glycine inhibits the growth of B16 melanoma tumors in mice. Carcinogenesis. 1999;20:793\u20138.","journal-title":"Carcinogenesis."},{"key":"2686_CR16","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.3748\/wjg.15.1301","volume":"15","author":"AI Gomaa","year":"2001","unstructured":"Gomaa AI, Khan SA, Leen ELS. Diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2001;15:1301\u201314.","journal-title":"World J Gastroenterol"},{"key":"2686_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0168-3659(02)00320-6","volume":"86","author":"L Mu","year":"2003","unstructured":"Mu L, Feng SS. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release. 2003;86:33\u201348.","journal-title":"J Control Release"},{"key":"2686_CR18","doi-asserted-by":"publisher","unstructured":"Ahmad A, Fauzia E, Kumar M, Mishra RK, Kumar A, Khan MA, et al. Gelatin-coated polycaprolactone nanoparticle-mediated naringenin delivery rescue human mesenchymal stem cells from oxygen glucose deprivation-induced inflammatory stress. ACS Biomater Sci Eng. https:\/\/doi.org\/10.1021\/acsbiomaterials8b01081 .","DOI":"10.1021\/acsbiomaterials8b01081"},{"key":"2686_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1556-276X-10-1","volume":"10","author":"S Antonakakis","year":"2015","unstructured":"Antonakakis S, Sarantopoulou N, Trohopoulos E, Stefi PN, Kollia AL, Gavriil Z, et al. Selective aggregation of PAMAM dendrimer nanocarriers and PAMAM\/ZnPc nanodrugs on human atheromatous carotid tissues: a photodynamic therapy for atherosclerosis. Nanoscale Res Lett. 2015;10:1\u201319.","journal-title":"Nanoscale Res Lett"},{"key":"2686_CR20","doi-asserted-by":"crossref","unstructured":"Kamalzadeh Z, Babanezhad E, Ghaffari S, Mohseni EA, Mahdieh M, Mehdi N, et al. Determination of bortezomib in API samples using hplc: assessment of enantiomeric and diastereomeric impurities. J Chromatogr Sci. 2017:1\u20139.","DOI":"10.1093\/chromsci\/bmx023"},{"key":"2686_CR21","first-page":"149","volume":"52","author":"AK Singhai","year":"1997","unstructured":"Singhai AK, Jain S, Jain NK. Evaluation of an aqueous injection of ketoprofen. Pharmazie. 1997;52:149\u201351.","journal-title":"Pharmazie"},{"key":"2686_CR22","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1016\/j.biomaterials.2007.04.004","volume":"28","author":"P Agarwal","year":"2007","unstructured":"Agarwal P, Gupta U, Jain NK. Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate. Biomaterials. 2007;28:3349\u201359.","journal-title":"Biomaterials."},{"key":"2686_CR23","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1007\/s11095-017-2238-8","volume":"34","author":"V Kushwah","year":"2017","unstructured":"Kushwah V, Agrawal AK, Dora CP. Novel gemcitabine conjugated albumin nanoparticles: a potential strategy to enhance drug efficacy in pancreatic cancer treatment. Pharm Res. 2017;34:2295\u2013311.","journal-title":"Pharm Res"},{"key":"2686_CR24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ejps.2017.10.008","volume":"111","author":"S Thakkar","year":"2018","unstructured":"Thakkar S, Sharma D, Misra M. Comparative evaluation of electro spraying and lyophilization techniques on solid state properties of Erlotinib nanocrystals: assessment of in-vitro cytotoxicity. Eur J Pharm Sci. 2018;111:257\u201369.","journal-title":"Eur J Pharm Sci"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-019-2686-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-019-2686-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-019-2686-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T18:04:48Z","timestamp":1664388288000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-019-2686-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,13]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["2686"],"URL":"https:\/\/doi.org\/10.1007\/s11095-019-2686-4","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,13]]},"assertion":[{"value":"13 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"160"}}